Evolus/$EOLS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Evolus

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Ticker

$EOLS
Primary listing

Industry

Pharmaceuticals

Employees

372

Evolus Metrics

BasicAdvanced
$614M
-
-$0.89
0.98
-

What the Analysts think about Evolus

Analyst ratings (Buy, Hold, Sell) for Evolus stock.

Bulls say / Bears say

Evolus reported its first-ever adjusted quarterly profit in Q2 2024, driven by strong sales of its Botox competitor, Jeuveau, indicating successful market penetration and operational efficiency. (reuters.com)
The company has captured 13% of the U.S. neuromodulator market within five years, showcasing its ability to compete effectively against established players. (finviz.com)
Evolus plans to diversify its product line with the upcoming launch of Evolysse, a premium dermal filler, potentially adding approximately $200 million to its revenue over time. (finviz.com)
Evolus reported a quarterly adjusted loss of 15 cents per share for Q1 2025, indicating ongoing challenges in achieving consistent profitability. (tradingview.com)
The company's debt-to-equity ratio stands at 23.54, significantly higher than industry norms, suggesting potential financial strain and increased risk. (nasdaq.com)
Evolus's return on equity (ROE) is -119.02%, indicating difficulties in efficiently utilizing equity capital and delivering satisfactory returns to shareholders. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Evolus Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Evolus Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EOLS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs